Bausch + Lomb pushes dry eye therapy to Phase 3 after Phase 2 miss
Bausch + Lomb disclosed that its dual-action dry eye drop failed to meet its primary endpoint in a Phase 2 study. Despite the setback, CEO Brent Saunders expressed optimism about the results, calling them a better outcome than anticipated. The company intends to advance the candidate into a Phase 3 trial.
Dry eye disease remains one of the most common ophthalmic conditions, affecting millions who seek relief from chronic discomfort and visual disturbance. In this competitive therapeutic area, a Phase 2 miss on a primary endpoint typically raises questions about a drug’s future. However, Bausch + Lomb’s decision to move its dual-action candidate into Phase 3 suggests the company sees meaningful signals in the secondary data or tolerability profile, even if the main goal was not achieved. The CEO’s framing of the outcome as “better than anticipated” indicates that internal expectations may have been low, and the observed effect, while not statistically significant, could still be clinically promising. Advancing to a larger trial carries financial and regulatory risk, but for a company with a substantial eye-care portfolio, investing in a potential first-in-class therapy may be a calculated bet. The Phase 3 design will need to address the shortcomings of the earlier study, likely with refined endpoints or patient selection.
If this therapy ultimately succeeds, patients with chronic dry eye could gain a new option that targets multiple pathways, potentially improving symptom control and quality of life. However, the Phase 2 miss means efficacy is unproven, and a Phase 3 failure would delay or eliminate that hope. Investors and healthcare providers may watch closely, as positive results could shift treatment patterns and market dynamics, while negative data might reinforce caution about dual-action approaches. The impact is most direct for patients who have exhausted existing treatments, but it also affects payers and competitors assessing the value of novel mechanisms.